

Healthcare Innovations Trust

Series 6

A 2 Year Unit Investment Trust

Healthcare Industry

Scientific innovations are driving opportunities in the healthcare industry. The increasing understanding of the disease mechanism, genomics enabling precision medicine, and improved therapeutics have been significant catalysts to the spending and investments in healthcare.

In addition to innovation, demographics are driving overall demand. Consider the following:

- Increase in life expectancies
- Aging population (more than 1.4 billion of population will be over the age of 60 by 2030)
- Half of all lifetime care expenditures occur from the age of 65 and upwards
- Increase in rate of chronic illnesses globally

Innovation and demographics present opportunities for investors in the healthcare industry.

Investment Objective

The trust seeks total return potential through capital appreciation. There is no guarantee that the investment objectives of the trust will be achieved.

Investment Strategy

The trust seeks to pursue its objective by investing in a portfolio consisting of equity securities comprising the Poliwogg Healthcare Innovation Index (PHIX).



About the Healthcare Innovation Index

Poliwogg's focus is on innovation and biotechnology (biotech), not big pharmaceutical companies. Typically, pharmaceutical drugs target symptoms of diseases. Conversely, biotech drugs target the underlying diseases themselves. Big pharma's preferred approach to biotech is through acquisition. This particular index is designed to isolate biotech companies that are potential takeover targets. Index inclusion criteria includes, but is not limited to:

Biotech companies with at least one drug in phase II or III clinical trial which meet one of the following criteria:

- Expected catalyst event date within 24 months
- Drug designation of breakthrough, fast track, or orphan

About the Research Provider

Poliwogg is a financial services company that creates unique tools which give market participants and investors access to specific verticals in the healthcare economy. Poliwogg products categorize investments in a number of different ways: by risk, by sector/subsector, and by particular diseases. Poliwogg's management team has extensive experience in finance, healthcare, and investing. It combines that expertise with a passion for increasing and broadening investment in healthcare and for using financial tools to increase efficiency and transparency in healthcare.

Description of Portfolio

INCEPTION DATE:	November 1, 2018
TERMINATION DATE:	November 4, 2020
INITIAL OFFER PRICE:	\$10.00
MINIMUM INVESTMENT:	100 units (may vary by selling firm)
NUMBER OF ISSUES:	30
DISTRIBUTIONS: ¹	MONTHLY (if any)
EST. NET ANNUAL 1ST YR DISTRIBUTIONS: ²	\$0.0000 (per unit)
CUSIP (CASH):	83201W 102
CUSIP (REINVESTMENT):	83201W 110
FEE-BASED CUSIP (CASH):	83201W 128
FEE-BASED CUSIP (REINVESTMENT):	83201W 136
TICKER:	SMHCFX

¹Distributions, if any, will be made commencing on December 25, 2018. The estimated net annual distribution is expected to decline over time because a portion of the securities included in the portfolio will be sold to pay for organization costs, creation and development fee and deferred sales charge. Distributions will fluctuate as a result of unitholder redemptions in addition to securities being sold within the portfolio. Distributions are also subject to the ability of issuers to make dividend payments in the future.

²Estimated Net Annual First Year Distribution per unit is computed by dividing the estimated annual income of the underlying securities less the expense per unit by the number of units outstanding. The estimated net annual distributions for subsequent years are expected to be less than estimated distributions for the first year because a portion of the securities included in the trust portfolio will be sold during the first year to pay for organization costs, the creation and development fee and the deferred sales charge. The actual net annual distributions will vary with changes in the trust's fees and expenses and income of the underlying securities.

Investors should consider the trust's investment objective, risks, charges and expenses carefully before investing. The prospectus contains this and other information relevant to an investment in the trust. Please read the prospectus carefully before you invest. If a prospectus did not accompany this literature, please contact SmartTrust at (888) 505-2872 to obtain a free prospectus.

Hennion & Walsh is a member of FINRA/SIPC.

2001 Route 46, Waterview Plaza, Parsippany, NJ 07054 (888) 505-2872 www.smarttrustuit.com

NOT FDIC INSURED • NOT BANK GUARANTEED • MAY LOSE VALUE

Sales Charges³ (based on a \$10 public offering price)

Standard Accounts

Transactional Sales Charge:	Initial	0.00%
	Deferred	2.25%
Creation & Development Fee ⁴ :		0.50%
Maximum Sales Charge:		2.75%

The initial sales charge is paid at the time of purchase and is the difference between the total sales charge (maximum of 2.75% of the public offering price) and the sum of the remaining deferred sales charge and the total creation and development fee. When the public offering price per unit is less than or equal to \$10, you will not pay an initial sales fee. When the public offering price per unit is greater than \$10 per unit, you will pay an initial sales fee.

The deferred sales charge is a charge of \$0.225 per unit and will be deducted in three monthly installments commencing on May 20, 2019. The initial and deferred sales fees do not apply to fee-based accounts. Please see the prospectus for sales charge details.

Fee/Wrap Accounts

Creation & Development Fee ⁴ :	0.50%
Maximum Sales Charge:	0.50%

³Percentages are based on a \$10.00 per unit offering price. For unit prices other than \$10.00, percentages of initial sales charge, creation and development fee, and deferred sales charges will vary. Early redemption will still cause payment of the deferred sales charge. The table above shows the initial offering period sales charges only.

⁴The creation and development fee is a charge of \$.050 per unit collected at the end of the initial offering period. If the price you pay exceeds \$10 per unit, the creation and development fee will be less than 0.50%; if the price you pay is less than \$10 per unit, the creation and development fee will exceed 0.50%. In addition to the sales charges listed, UITs are subject to annual operating expenses and organization costs.

Portfolio Holdings as of November 1, 2018:

Equity Securities — 100.00%	
Health Care — 100.00%	
ACAD	ACADIA Pharmaceuticals Inc.
ACOR	Acorda Therapeutics, Inc.
AGIO	Agios Pharmaceuticals, Inc.
AIMT	Aimmune Therapeutics, Inc.
ALDR	Alder BioPharmaceuticals, Inc.
ALXN	Alexion Pharmaceuticals, Inc.
ANAB	AnaptysBio, Inc.
APLS	Apellis Pharmaceuticals, Inc.
ARNA	Arena Pharmaceuticals
ATNX	Athenex, Inc.
BHVN	Biohaven Pharmaceutical Holding Company Ltd.
DBVT	DBV Technologies S.A.
EBS	Emergent BioSolutions Inc.
FGEN	FibroGen, Inc.
GBT	Global Blood Therapeutics, Inc.
GWPH	GW Pharmaceuticals plc
HZNP	Horizon Pharma plc
IMGN	ImmunoGen, Inc.
ICPT	Intercept Pharmaceuticals, Inc.
IOVA	Iovance Biotherapeutics, Inc.
KPTI	Karyopharm Therapeutics Inc.
MDCO	The Medicines Company
MRTX	Mirati Therapeutics, Inc.
MYOV	Myovant Sciences Ltd.
PCRX	Pacira Pharmaceuticals, Inc.
PBYI	Puma Biotechnology, Inc.
RDUS	Radius Health, Inc.
RVNC	Revanche Therapeutics, Inc.
SUPN	Supernus Pharmaceuticals, Inc.
TSRO	TESARO, Inc.

Risk Considerations

Unitholders can lose money by investing in this trust. An investment in units of the trust should be made with an understanding of the risks related to the trust, such as the following:

- Security prices will fluctuate. The value of your investment may fall over time.
- The financial condition of an issuer may worsen or its credit ratings may drop, resulting in a reduction in the value of your units. This may occur at any point in time, including during the initial offering period.
- The issuer of a security may be unwilling or unable to declare dividends in the future or may reduce the level of dividends declared. This may reduce the level of distributions the trust pays which could reduce your income and cause the value of your units to fall.
- The trust's selection starts with the securities from the Poliwogg Index selected prior to the date of the trust's formation. The trust's portfolio may not include all securities in the Poliwogg Index and could include securities that are not included in the Poliwogg Index. The securities in the trust's portfolio will not change if the Poliwogg Index components, or their weightings within the Poliwogg Index, change. The performance of the trust may not correspond with the Poliwogg Index for this reason and because the trust incurs a sales charge and expenses.
- The trust is considered to be concentrated in securities issued by companies in the health care sector. Negative developments in this sector will affect the value of your investment more than would be the case in a more diversified investment. General risks of companies in the health care sector include extensive competition, generic drug sales, the loss of patent protection, product liability litigation, increased government regulation, and challenges in obtaining regulatory approval for drugs and therapies.
- The trust may invest in stocks of small and mid-size companies. These stocks are often more volatile and have lower trading volumes than stocks of larger companies. Small and mid-size companies may have limited products or financial resources, management inexperience and less publicly available information.
- The trust is not actively managed. Except in limited circumstances, the trust will hold, and continue to buy, shares of the same securities even if their market value declines.
- The sponsor may offer successive trusts with similar portfolios thereby allowing the investor to pursue the same strategy over a number of years. Investors should consider their ability to pursue investing in successive trusts, if available. There may be tax consequences associated with investing in the trust and rolling over an investment from one trust to the next.